Data from an open-label trial showed that foralumab treatment eased fatigue and lessened disability for some people with ...

Intranasal foralumab, developed by biotech company ... million grant from the National Institute on Aging to study the nasal spray for Alzheimer’s, just a few months after the FDA approved ...

A new study led by researchers at Mass General Brigham suggests a nasal spray developed to target neuroinflammation could one ...

This comprehensive study demonstrated that nasal foralumab was safe, induced potent regulatory immune responses, reduced microglial activation, and stabilized clinical progression in patients ...

which comes in the form of a nasal spray, to target the neuroinflammatory process. When they tested the antibody – known as Foralumab – in mouse models of moderate to severe TBI, the team ...

Modulating the neuroinflammatory response using the nasal spray, Izzy said ... The study examines the monoclonal antibody Foralumab, made by Tiziana, which has been tested in clinical trials ...

Ten patients with na-SPMS, who continued to progress despite B-cell therapy, were treated with nasal foralumab for a minimum of six months. No serious or severe treatment-related adverse events ...

In parallel with these encouraging results, Tiziana Life Sciences has initiated a randomized, double-blind, placebo-controlled Phase 2 clinical trial to further assess the efficacy and safety of nasal ...